Comparing Calithera Biosciences (NASDAQ:CALA) & ScPharmaceuticals (NASDAQ:SCPH)
Comparing Calithera Biosciences (NASDAQ:CALA) & ScPharmaceuticals (NASDAQ:SCPH)
scPharmaceuticals (NASDAQ:SCPH – Get Rating) and Calithera Biosciences (NASDAQ:CALA – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, institutional ownership and valuation.
SCCharery（NASDAQ：SCPH-獲得評級）和卡利瑟拉生物科學（NASDAQ：CALA-獲取評級）都是小型醫療公司，但哪個是更好的投資？我們將根據兩家企業的風險，收益，分析師建議，股息，盈利能力，機構所有權和估值來對比這兩家企業。
Insider & Institutional Ownership
內幕和機構所有權
53.9% of scPharmaceuticals shares are owned by institutional investors. Comparatively, 33.7% of Calithera Biosciences shares are owned by institutional investors. 4.7% of scPharmaceuticals shares are owned by company insiders. Comparatively, 6.6% of Calithera Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
53.9% 的中國藥業股份由機構投資者擁有。相比之下，33.7％ 的卡利瑟拉生物科學股份由機構投資者擁有。中國藥業的 4.7％ 股份由公司內部人員擁有。相比之下，6.6％ 的卡利塞拉生物科學股份由公司內部人士擁有。強大的機構所有權表明對沖基金，捐贈基金和大型資金經理認為股票有望實現長期增長。
Volatility and Risk
波動性和風險
scPharmaceuticals has a beta of 0.22, indicating that its stock price is 78% less volatile than the S&P 500. Comparatively, Calithera Biosciences has a beta of 1.22, indicating that its stock price is 22% more volatile than the S&P 500.
中國藥業的測試值為 0.22，表明其股票價格比標普 500 低 78％ 的波動性。相比之下，卡里瑟拉生物科學的測試值為 1.22，表明其股票價格比標普 500 波動性高 22％。
Profitability
盈利
This table compares scPharmaceuticals and Calithera Biosciences' net margins, return on equity and return on assets.
此表格比較了中國藥業和卡利瑟拉生物科技的淨利潤率、權益回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| scPharmaceuticals | N/A | -78.70% | -54.65% |
| Calithera Biosciences | N/A | -919.76% | -103.32% |
| 淨利潤 | 權益回報率 | 資產回報率 | |
| 中國藥業 | N/A | -78.70% | -54.65% |
| 卡利瑟拉生物科學 | N/A | -919.76% | -103.32% |
Analyst Recommendations
分析師推薦
This is a breakdown of recent ratings and recommmendations for scPharmaceuticals and Calithera Biosciences, as reported by MarketBeat.com.
這是由 MarketBeat.com 報導的最近評級和建議的細分。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| scPharmaceuticals | 0 | 0 | 6 | 0 | 3.00 |
| Calithera Biosciences | 0 | 2 | 1 | 0 | 2.33 |
| 銷售評級 | 保留評分 | 購買評級 | 強大的買入評級 | 評級分數 | |
| 中國藥業 | 0 | 0 | 6 | 0 | 3.00 |
| 卡利瑟拉生物科學 | 0 | 2 | 1 | 0 | 2.33 |
scPharmaceuticals currently has a consensus target price of $18.00, indicating a potential upside of 107.85%. Calithera Biosciences has a consensus target price of $18.67, indicating a potential upside of 41,381.48%. Given Calithera Biosciences' higher possible upside, analysts plainly believe Calithera Biosciences is more favorable than scPharmaceuticals.
中國藥業目前的共識目標價為 18.00 美元，表明潛在的上行空間為 107.85％。卡利瑟拉生物科學的共識目標價格為 18.67 美元，表明潛在的上行空間為 41,381.48％。鑑於卡利瑟拉生物科學 '更高的上漲空間, 分析師清楚地認為卡里瑟拉生物科學比 SCPharies 更有利.
Earnings and Valuation
收益及估值
This table compares scPharmaceuticals and Calithera Biosciences' revenue, earnings per share and valuation.
此表比較了藥業和卡利瑟拉生物科技的收入，每股收益和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| scPharmaceuticals | N/A | N/A | -$28.03 million | ($1.30) | -6.66 |
| Calithera Biosciences | $9.75 million | 0.02 | -$115.09 million | ($25.60) | 0.00 |
| 總收入 | 價格/銷售比率 | 淨收入 | 每股盈利 | 市盈比率 | |
| 中國藥業 | N/A | N/A | -28.3 百萬美元 | (一元三十元) | -6.66 |
| 卡利瑟拉生物科學 | 九百七十五萬美元 | 0.02 | -一億一千五百零九萬元 | (二十五點六十元) | 0.00 |
scPharmaceuticals has higher earnings, but lower revenue than Calithera Biosciences. scPharmaceuticals is trading at a lower price-to-earnings ratio than Calithera Biosciences, indicating that it is currently the more affordable of the two stocks.
中國藥業的收益較高，但收入低於卡利瑟拉生物科學，其價格與盈利比率低於卡利瑟拉生物科學，這表明兩隻股票目前價格比較實惠。
Summary
摘要
scPharmaceuticals beats Calithera Biosciences on 7 of the 12 factors compared between the two stocks.
SCPharery 在 7 的 12 因素中擊敗了卡利塞拉生物科學兩隻股票之間的 12 個因素。
About scPharmaceuticals
關於中國藥業
(Get Rating)
(取得評分)
scPharmaceuticals, Inc. engages in the development of transformative pharmaceutical products for subcutaneous delivery. Its products include FUROSCIX, a furosemide injection which is used as parenteral diuretic in treating heart failure and scCeftriaxone, used as parenteral antibiotic outside the hospital setting. The company was founded by Pieter Muntendam and Bertram Pitt in February 2013 and is headquartered in Burlington, MA.
SCPharcienCharery 公司從事用於皮下遞送的變革性醫藥產品的開發。其產品包括 FURSCIX，一種呋塞米注射液，用作腸外利尿劑治療心力衰竭和 SCCEFtriaxone，在醫院環境外用作腸外抗生素。該公司由彼得蒙滕丹和伯特拉姆皮特於 2013 年 2 月成立，總部位於馬薩諸塞州伯靈頓。
About Calithera Biosciences
關於卡利瑟拉生物科學
(Get Rating)
(取得評分)
Calithera Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on discovering and developing small molecule drugs that target novel and critical metabolic pathways in tumor and cancer-fighting immune cells. It offers programs such as Pipeline, Glutaminase Inhibitor, and Arginase Inhibitor. The company was founded by James A. Wells and Susan M. Molineaux on March 9, 2010 and is headquartered in South San Francisco, CA.
Calithera Biosciences, Inc. 是一家臨床階段生物製藥公司，致力於發現和開發針對腫瘤和抗癌免疫細胞中新穎和關鍵代謝途徑的小分子藥物。它提供了程序，如管道, 谷氨酰胺酶抑制劑, 和精氨酸酶抑制劑.該公司由詹姆斯 ·A· 威爾斯和蘇珊·莫利諾於 2010 年 3 月 9 日創立，總部位於加利福尼亞州南舊金山。
Receive News & Ratings for scPharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for scPharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
接收《中國藥業日報》的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 SCPharies 和相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。